Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Globe Newswire•29/09/2026•07:00 ET
0
Key Highlights
- ➤Full-year 2026 revenue guidance raised to $410 to $420 million
- ➤Guidance midpoint increased $55 million, or ~15%, from $350 to $370 million
- ➤Amtagvi and Proleukin demand drives nearly 60% projected annual revenue growth
- ➤Q2 2026 total product revenue reached record $99.3 million
- ➤Authorized treatment center network targets at least 110 centers by year-end 2026
Expert Statements
Frederick Vogt, Interim President and Chief Executive Officer of Iovance Biotherapeutics
“Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint”
Frederick Vogt, Interim President and Chief Executive Officer of Iovance Biotherapeutics
“Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues.”
Frederick Vogt, Interim President and Chief Executive Officer of Iovance Biotherapeutics
“In addition, lifileucel continues to advance across our registrational programs in new solid tumor indications, while continued manufacturing and operating efficiencies accelerate our progress toward profitability.”
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million
Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook
Get started
Create a free account to read the full story.